BeyondSpring: Up as therapy for cancer patients meets main study goal

Beyondspring

16/11/2020 13:37

** Shares of drug developer  BYSI.O  rise 12.65% to $19.50
premarket
    ** Co reports positive top-line data from late-stage study
of combination therapy involving its lead therapeutic candidate
plinabulin to treat a side-effect of chemotherapy in cancer
patients  urn:newsml:reuters.com:*:nGNX57Y0w1
    ** Co says patients in trial were treated with plinabulin -
an immune and stem cell modulator - in combination with
pegfilgrastim, which helps stimulate production of white blood
cells 
    ** BYSI says study met primary goal of showing statistically
significant improvement in rate of prevention of Grade 4
neutropenia - a severe side effect of chemotherapy that
increases risk of infection with fever
    ** Plinabulin is currently in an Expanded Access Program in
the U.S. - co
    ** Up to last close, BYSI stock up 11.6% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))